Recent progress of the laboratory in the area of the search and development of novel remedies for prophylaxis and treatment of influenza is reviewed in this work. The data of the study of the anti-viral activity of compounds from the chemical groups of azolo-adamantanes, triterpenes, derivatives of benzimidazole, usnic acid, and other heterocyclic substances are presented. The protective properties of the plant antioxidants at lethal influenza infection of animals are discussed. High virus-inhibiting activity of natural polysaccharides and their complexes with silver ions is shown against influenza virus. The data presented allow listed groups of compounds to be suggested as promising candidates for further development of anti-influenza drugs.

Download full-text PDF

Source

Publication Analysis

Top Keywords

influenza virus
8
[development novel
4
novel drugs
4
influenza
4
drugs influenza
4
virus based
4
based synthetic
4
synthetic natural
4
natural compounds]
4
compounds] progress
4

Similar Publications

Unlabelled: Zoonotic viruses are an omnipresent threat to global health. Influenza A virus (IAV) transmits between birds, livestock, and humans. Proviral host factors involved in the cross-species interface are well known.

View Article and Find Full Text PDF

Since late 2021, a panzootic of highly pathogenic H5N1 avian influenza virus has driven significant morbidity and mortality in wild birds, domestic poultry, and mammals. In North America, infections in novel avian and mammalian species suggest the potential for changing ecology and establishment of new animal reservoirs. Outbreaks among domestic birds have persisted despite aggressive culling, necessitating a re-examination of how these outbreaks were sparked and maintained.

View Article and Find Full Text PDF

The I38T substitution in the influenza virus polymerase-acidic (PA) subunit is a resistance marker of concern for treatment with the antiviral baloxavir marboxil (BXM). Thus, monitoring PA/I38T mutations is of clinical importance. Here, we developed three rapid and sensitive assays for the detection and monitoring of the PA/I38T mutation.

View Article and Find Full Text PDF

Next-generation vaccines for influenza B virus: advancements and challenges.

Arch Virol

January 2025

CAS Key Laboratory of Molecular Virology & Immunology, Institutional Center for Shared Technologies and Facilities, Pathogen Discovery and Big Data Platform, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Yueyang Road 320, Shanghai, 200031, China.

To battle seasonal outbreaks of influenza B virus infection, which continue to pose a major threat to world health, new and improved vaccines are urgently needed. In this article, we discuss the current state of next-generation influenza B vaccine development, including both advancements and challenges. This review covers the shortcomings of existing influenza vaccines and stresses the need for more-effective and broadly protective vaccines and more-easily scalable manufacturing processes.

View Article and Find Full Text PDF

The seasonality and epidemiology of viral acute respiratory infections (ARIs) have changed since the coronavirus disease 2019 pandemic. However, molecular-based ARI surveillance has not been conducted in Japan. We developed a regional surveillance program to define the local epidemiology of ARIs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!